

YONDELIS® (trabectedin)

Concomitant Use of YONDELIS with Other Non-Janssen COVID-19 Vaccines

SUMMARY

- **Use with other non-Janssen COVID-19 Vaccines**
 - Currently, there are no published studies on the concomitant use of other manufacturers' COVID-19 vaccines and YONDELIS.
 - Clinicians should use clinical judgement based on local/institutional guidelines, standards of care, and individual patient risk/benefit assessment when considering concomitant use of YONDELIS and the other COVID-19 vaccine.
 - For additional information regarding the use of other non-Janssen COVID-19 vaccines, please contact the vaccine manufacturer.
- **General Vaccination Information**
 - Cancer organizations, including the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) have published healthcare professional resources related to COVID-19 vaccination and patients with cancer, visit: [Recommendations of the NCCN COVID-19 Vaccination Advisory Committee](#), [ASCO: COVID-19 Vaccines & Patients with Cancer](#), and [ESMO Statements on Vaccination Against COVID-19 in People with Cancer](#).¹⁻³ Please note: This list is not all inclusive and is subject to change.
 - Refer to the Centers for Disease Control (CDC) and Prevention Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Recommendations, Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, and General Best Practice Guidelines for Altered Immunocompetence. For more information, including additional mRNA COVID-19 vaccine dose recommendations for patients with solid tumor malignancies receiving active treatment, visit: [COVID-19 ACIP Vaccine Recommendations](#), [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#), and [General Best Practice Guidelines for Immunization, Altered Immunocompetence](#).⁴⁻⁶

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 12 August 2024.

REFERENCES

1. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee. NCCN. Accessed 2024-08-12. Available via: https://nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v3-0.pdf?sfvrsn=b483da2b_60.
2. COVID-19 vaccines & patients with cancer. American Society of Clinical Oncology (ASCO). Accessed 2024-08-12. Available via: <https://asco.org/covid-resources/vaccines-patients-cancer>.
3. ESMO statements on vaccination against COVID-19 in people with cancer. (ESMO) European Society for Medical Oncology. Accessed 2024-08-12. Available via: <https://esmo.org/covid-19-and-cancer/covid-19-vaccination?hit=ehp>.
4. COVID-19 ACIP vaccine recommendations. Centers for Disease Control and Prevention (CDC). Accessed 2024-08-12. Available via: <https://cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>.
5. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention. Accessed 2024-08-12. Available via: <https://cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>.

6. Altered Immunocompetence General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. Accessed 2024-08-12. Available via: <https://cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>.